Mainz, Germany

Ozlem Tureci

This inventor holds 53 USPTO granted patents and 22 published patent applications and 1 EPO patent, primarily in Cancer Immunotherapy (CPC class C07K). Top assignees: Ganymed Pharmaceuticals Ag, Johannes Gutenberg-Universität Mainz, Astellas Pharma Gmbh. Active years: 2004-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ozlem Tureci. Retrieved from https://idiyas.com/inventor/ozlem-tureci

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 53 

% Patents Active = 81.1


Average Co-Inventor Count = 4.8

ph-index = 10

Forward Citations = 265(Granted Patents)

Forward Citations (Not Self Cited) = 190(Dec 10, 2025)


Inventors with similar research interests:


Company Filing History:

goldMedal20 out of 50 
 
Ganymed Pharmaceuticals Ag
 patents
silverMedal15 out of 45 
 
Johannes Gutenberg-Universität Mainz
 patents
bronzeMedal13 out of 424 
 
Astellas Pharma Gmbh
 patents
4. 11 out of 37 
 
Biontech Ag
 patents
5. 7 out of 25 
 
Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh
 patents
6. 4 out of 8 
 
Biontech Cell & Gene Therapies Gmbh
 patents
7. 3 out of 10 
 
Ganymed Pharmaceuticals Gmbh
 patents
8. 3 out of 14 
 
Tron-Translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz
 patents
9. 2 out of 74 
 
Biontech Se
 patents
10. 2 out of 4 
 
Johannes Gutenberg Universität
 patents
11. 2 out of 3 
 
Translationale Onkologie an Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh
 patents
12. 2 out of 16 
 
Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh
 patents
13. 2 out of 18 
 
Universitätsmedizin Der Johannes Gutenberg-Universitat Mainz
 patents
14. 1 out of 1 
 
Biontech Protein Therapeutics Gmbh
 patent
15. 1 out of 530 
 
Ludwig Institute for Cancer Research Limited
 patents
16. 1 out of 1 
 
Translationale Onkologie an Der Universitätsmedizin Der Johannes Gutenbera-Universität Mainz Gemeinnützine Gmbh
 patent
17. 1 out of 1 
 
Tron - Translationale Onkologie an Der Universitatsmedizin Der Johannes
 patent
18. 1 out of 2 
 
Tron Ggmbh
 patents
19. 1 out of 3 
 
Tron Translationale Onkologie an Der Universitatsm
 patents
20. 1 out of 3 
 
Tron—translationale Onkologie an Der Universitat
 patents
21. 1 out of 1 
 
Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat at Mainz Gemeinnutzige Gmbh
 patent
22. 1 out of 1 
 
Tron—translationale Onkologie an Der Univresitätsmedizin Der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh
 patent
23. 1 out of 1 
 
Tron—translationale Onkologie an Der Untversitatsmedizin Der Johannes Gutenberg-Universit Mainz Ggmbh
 patent
24. 1 out of 1 
 
Universitätsmedizin Der Johannes Gutenberg-Universität
 patent
25. 1 out of 834,453 
Other
 patents
where one patent can have more than one assignee

Years Active: 2004-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Cancer Therapy
Antibody Therapy
RNA Modification
Claudin 18.2
Tumor Diagnosis
Combination Therapy
Cancer Prognosis
Immunoreceptors
Cancer Stem Cells
Monoclonal Antibodies
T Cell Epitopes
Claudin 6
53 patents (USPTO):Explore Patents

Title: Ozlem Tureci: Pioneering Medical Research and Innovation

Introduction:

Ozlem Tureci is a prominent figure in the field of medical research, having made significant contributions to the development of novel therapeutics for various diseases. Co-founder of the biotechnology company BioNTech, Tureci's expertise in the field of oncology has led to numerous milestones and recognition throughout his career.

Latest Patents:

Tureci's extensive contributions to medical research include the development of groundbreaking patents. His latest patents demonstrate his commitment to finding effective treatments for cancer-related diseases. One such patent involves the use of antibodies for the treatment of cancer expressing claudin 6. This innovation has the potential to address a wide range of tumor-related diseases including ovarian, lung, gastric, and breast cancer, among others. Additionally, Tureci's patent on a combination therapy involving antibodies against claudin 18.2 has shown promising results in the treatment of metastatic pancreatic adenocarcinoma.

Career Highlights:

Tureci's career has been marked by remarkable achievements in the field of medical research. With a total of 49 patents to his name, Tureci has consistently demonstrated his dedication to advancing the treatment of various diseases. His expertise transcends academia and into the business realm, as evidenced by his co-founding of BioNTech. This biotechnology company has quickly risen to prominence under his guidance, further solidifying Tureci's reputation as a leader in the industry.

Collaborations:

Throughout his career, Tureci has collaborated with esteemed professionals in the medical research field. Notable collaborators include Ugur Sahin and Michael Koslowski. Their combined expertise and collaborative efforts have paved the way for groundbreaking advancements in cancer treatment.

Conclusion:

Ozlem Tureci's exceptional contributions to medical research, highlighted by his numerous patents and innovative therapies, have positioned him as a trailblazer in the field. Through his co-founding of BioNTech and collaborations with renowned experts, Tureci continues to revolutionize the treatment of various cancers. His tireless dedication and commitment to innovation serve as an inspiration to aspiring researchers and inventors alike, leaving an indelible impact on the field of medical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…